Report Back From SABCS 2025: Key Clinical Trial Updates in MBC
What do the latest findings from the 2025 San Antonio Breast Cancer Symposium mean for people living with metastatic breast cancer?
In this episode, Dr. Bora Lim of MD Anderson Cancer Center joins us to break down the most impactful research and clinical trial updates from SABCS 2025. Together we will explore advances in hormone receptor positive, HER2-positive disease and triple negative disease and discuss how these updates may influence treatment decisions right now. We also wrap up with an audience Q&A, including questions about GLP-1 medications.
Listen in for expert insight, practical takeaways, and clarity on the evolving MBC treatment landscape.
Meet the Guest of the Episode
Bora Lim, MD
Dr. Lim is a renowned clinical-translational investigator specializing in oncology, with a deep-rooted commitment to addressing the challenges of metastatic and inflammatory breast cancer. Dr. Lim is highly invested in clinical and research efforts to understand ‘difficult-to-treat’ cancers like IBC, treatment refractory triple negative breast cancers and other rare breast cancers by organizing team science and adopting/ applying cutting edge technologies matching with effective, novel therapeutics. A notable recent breakthrough from her studies is the role of non-coding RNA in breast cancer, inflammatory breast cancer TME, single cell genomic and transcriptomic analysis of normal and advanced breast cancer tissues, novel blood biomarker and development of such biomarker -integrated clinical trials. She is currently serving as a translational lead for both Breast Medical Oncology department and Morgan Welch IBC Research and Clinic program at the UT MD Anderson Cancer Center.
